Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer

NCT03519230 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT03519230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03519230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Lead sponsor
BeiGene
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 14, 2018
Completion date
January 30, 2027
Enrollment
224 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer